Benitec Biopharma Ltd (NASDAQ:BNTC)

3.13
Delayed Data
As of Jul 13
 -0.04 / -1.26%
Today’s Change
1.85
Today|||52-Week Range
4.90
+5.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$26.5M

Company Description

Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments. The company was founded by Kenneth C. Reed in 1997 and is headquartered in North Sydney, Australia.

Contact Information

Benitec Biopharma Ltd.
Suite 1201
North Sydney New South Wales (nsw) 2060
P:(129) 555-6986
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Bryan DulhuntyChief Financial Officer
Georgina H. KilfoilChief Clinical & Development Operations Officer
Gregory C. WestCo-Secretary
Oliver KiddCo-Secretary